Recent progress in Helicobacter pylori treatment
10.1097/CM9.0000000000000618
- VernacularTitle:Recent progress in Helicobacter pylori treatment
- Author:
Yi HU
1
;
Yin ZHU
;
Nong-Hua LU
Author Information
1. Department of Gastroenterology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, China.
- Keywords:
Helicobacter pylori;
Bismuth, dual therapy;
Vonoprazan;
Probiotics;
Vitamin
- From:
Chinese Medical Journal
2020;133(3):335-343
- CountryChina
- Language:Chinese
-
Abstract:
The main challenge in the field of Helicobacter pylori ( H. pylori) infection is antibiotic resistance, which influences the efficacy of eradication regimens. Bismuth-containing quadruple therapy has been confirmed as an effective regimen for eradicating H. pylori, especially in strains with antibiotic resistance. High-dose proton-pump inhibitor-amoxicillin dual therapy could decrease the use of unnecessary antibiotics, which is a promising alternative approach. Adjuvant therapy (specific probiotic or vitamin) also showed good results, although more evidence is needed. Novel anti- H. pylori drugs are needed, and the establishment of the H. pylori database is an effective way to acknowledge the real-time information of H. pylori management. This review provides the recent progress of H. pylori treatment, and further studies are needed to address the role of different regimens in improving H. pylori eradication rate, especially in strains with antibiotics resistance.
